Thursday 16 October, 2025
Objectives: Cobicistat, a potent CYP3A4 inactivator that was developed specifically as a pharmacokinetic enhancer, is given in combinations with antiretrovirals…
Read morePoster: Drug/Disease Modelling - Infection
Population pharmacokinetic modelling of dolutegravir, tenofovir and emtricitabine in non-human primates
Thursday 16 October, 2025
Objectives: Current antiretroviral treatment (ART) is effective in achieving and maintaining undetectable plasma HIV-RNA levels but it does not eradicate…
Read moreModelling of plasma unbound Ceftriaxone: can we improve efficacy in clinical practice ?
Thursday 16 October, 2025
Introduction: Ceftriaxone, a third generation semisynthetic cephalosporin with a long half-life, is a cornerstone antibiotic for critically ill patients with…
Read moreIdentification and quantification of variability in the microdialysis technique using mixed-effects modelling within an integrated in vitro and ex vivo approach: a linezolid case study.
Thursday 16 October, 2025
Objectives: In the treatment of infections, the unbound drug concentration at the target site, i.e. the interstitial space fluid (ISF), is…
Read moreUnderstanding variability in microdialysis measurements: introducing a combined calibration approach for piperacillin and tazobactam in LPS-induced septic piglets
Thursday 16 October, 2025
Objectives: Case fatality rates of septic children are reported at 20% [1]. Inadequate target tissue exposure is hypothesised to lead…
Read morePopulation pharmacokinetics of rifampicin and 25-O-desacetyl-rifampicin in Brazilian patients with pulmonary tuberculosis living or not with HIV.
Thursday 16 October, 2025
Introduction: Rifampicin (RIF) is possibly the most important drug among the four first-line anti-tuberculosis drugs (FLATDs). Currently, the World Health…
Read morePopulation pharmacokinetics of amoxicillin in postpartum minipig plasma
Thursday 16 October, 2025
Objectives: Antibiotics are frequently prescribed to postpartum women and nursing mothers for prophylaxis and treatment of infections. In the latter…
Read moreA pooled pharmacokinetic analysis of piperacillin-tazobactam in different patient populations
Thursday 16 October, 2025
Objectives: Piperacillin-tazobactam is a β-lactam/β-lactamase inhibitor combination product used against severe infections in the intensive care unit setting[1]. However, pharmacokinetics…
Read morePhysiologically based pharmacokinetic (PBPK) modelling of drug-drug interactions between long-acting cabotegravir and rilpivirine with oral rifabutin
Thursday 16 October, 2025
Introduction: Tuberculosis remains the primary cause of death among people living with HIV [1]. First-line treatment for tuberculosis often includes…
Read morePopulation pharmacokinetics of dexamethasone in critically ill COVID-19 patients: does inflammation play a role?
Thursday 16 October, 2025
Objectives: One of the common causes of COVID-19 related death is acute respiratory distress syndrome (C-ARDS). Dexamethasone is the cornerstone…
Read more